SAI PARENTERALS SHARE PRICE

Sai Parenteral`s Limited was originally incorporated as `Sai Parenteral`s Private Limited`, a Private Limited Company on January 12, 2001, with the Registrar of Companies, at Hyderabad. Thereafter, Company was converted into a Public Limited Company and the name of Company was changed to `Sai Parenteral`s Limited` w.e.f January 17, 2022. The Company initially focused on manufacturing parenteral (injectables) formulations by the time the current management assumed leadership in 2016. Company has transitioned from manufacturer of parenteral formulations to a diversified formulations business spanning across multiple dosage forms, including injectables, tablets, capsules, liquid orals and ointments. This transition has been accompanied by the diversification of therapeutic areas. including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics and dermatology products. The Company acquired Unit-I and Unit-II in 2016. It launched Prefilled technology equipment at Unit-I in FY 2021. Company has undertaken strategic acquisitions that expanded the manufacturing, technological and CDMO capabilities, diversified the product range and increased geographical presence in regulated and semi regulated markets. In February 2022, Company acquired Unit III facility located at IDA Bhongir, Hyderabad and accredited by the Therapeutic Goods Administration (TGA), Australia. In September 2022, Company acquired Unit IV facility accredited with Pharmaceutical Inspection Co-operation Scheme (PIC/S) and WHO-GMP. It started the export business in 2023 after acquiring two internationally accredited manufacturing units in Hyderabad, Telangana. In February 2024, Company further expanded its domestic presence by making Revat Laboratories as a wholly owned subsidiary. The Company has incorporated a wholly owned subsidiary, Sai Parenterals Pte. Limited in Singapore in FY25. The Company came up with IPO aggregating the issuance of 10,428,288 equity shares of Rs 5 each and raised funds of Rs 408.78 crore, which comprises a fresh issue of 7,270,408 equity shares amounting to Rs 285 crore and the offer for sale of 3,157,880 equity shares amounting to Rs 123.78 crore on March 27, 2026.

Sai Parenterals share price as on 29 Aug 2026 is Rs. 521.35. Over the past 6 months, the Sai Parenterals share price has increased by 0% and in the last one year, it has increased by 28.51%. The 52-week low for Sai Parenterals share price was Rs. 400 and 52-week high was Rs. 706.

Sai Parenteral`s Limited was originally incorporated as `Sai Parenteral`s Private Limited`, a Private Limited Company on January 12, 2001, with the Registrar of Companies, at Hyderabad. Thereafter, Company was converted into a Public Limited Company and the name of Company was changed to `Sai Parenteral`s Limited` w.e.f January 17, 2022. The Company initially focused on manufacturing parenteral (injectables) formulations by the time the current management assumed leadership in 2016. Company has transitioned from manufacturer of parenteral formulations to a diversified formulations business spanning across multiple dosage forms, including injectables, tablets, capsules, liquid orals and ointments. This transition has been accompanied by the diversification of therapeutic areas. including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics and dermatology products. The Company acquired Unit-I and Unit-II in 2016. It launched Prefilled technology equipment at Unit-I in FY 2021. Company has undertaken strategic acquisitions that expanded the manufacturing, technological and CDMO capabilities, diversified the product range and increased geographical presence in regulated and semi regulated markets. In February 2022, Company acquired Unit III facility located at IDA Bhongir, Hyderabad and accredited by the Therapeutic Goods Administration (TGA), Australia. In September 2022, Company acquired Unit IV facility accredited with Pharmaceutical Inspection Co-operation Scheme (PIC/S) and WHO-GMP. It started the export business in 2023 after acquiring two internationally accredited manufacturing units in Hyderabad, Telangana. In February 2024, Company further expanded its domestic presence by making Revat Laboratories as a wholly owned subsidiary. The Company has incorporated a wholly owned subsidiary, Sai Parenterals Pte. Limited in Singapore in FY25. The Company came up with IPO aggregating the issuance of 10,428,288 equity shares of Rs 5 each and raised funds of Rs 408.78 crore, which comprises a fresh issue of 7,270,408 equity shares amounting to Rs 285 crore and the offer for sale of 3,157,880 equity shares amounting to Rs 123.78 crore on March 27, 2026.

Sai Parenterals share price as on 29 Aug 2026 is Rs. 521.35. Over the past 6 months, the Sai Parenterals share price has increased by 0% and in the last one year, it has increased by 28.51%. The 52-week low for Sai Parenterals share price was Rs. 400 and 52-week high was Rs. 706.